OncoMatch/Clinical Trials/NCT06698003
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Is NCT06698003 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Mogamulizumab for t-cell leukemia/lymphoma, adult.
Treatment: Mogamulizumab — The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: immunosuppressant
Prior treatment with immunosuppressants or interferon alpha products within 6 months prior to the date of enrollment
Cannot have received: interferon alpha
Prior treatment with immunosuppressants or interferon alpha products within 6 months prior to the date of enrollment
Cannot have received: other study drugs
Prior treatment with other study drugs within 4 months prior to giving informed consent
Lab requirements
Blood counts
Neutrophil count ≥1000/mm3 (unless ethnic neutropenia); Platelets ≥100,000/mm3; Hemoglobin ≥9.0 g/dL
Kidney function
Serum creatinine ≤1.5x ULN
Liver function
AST ≤1.5x ULN; ALT ≤1.5x ULN; Total bilirubin ≤1.5x ULN
Cardiac function
Blood oxygen saturation (SpO2) ≥90%; ECG: No abnormal findings requiring treatment
Primary organ functions are stable * Neutrophil count: ≥ 1000/mm3, unless patient has diagnosis of ethnic neutropenia * Platelets: ≥100,000/mm3 * Hemoglobin: ≥9.0 g/dL * Serum aspartate aminotransferase (AST): ≤1.5x upper limit of normal (ULN) * Alanine aminotransferase (ALT): ≤1.5x ULN * Total bilirubin: ≤1.5x ULN * Serum creatinine (Cr): ≤1.5x ULN * Blood oxygen saturation (SpO2): ≥90% * Electrocardiogram (ECG): No abnormal findings requiring treatment are observed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (All protocol activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All protocol activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06698003 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunosuppressant, interferon alpha, other study drugs disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify